Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Common Equity (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Common Equity for 11 consecutive years, with $18.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 146.84% to $18.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.4 million, a 146.84% increase, with the full-year FY2024 number at $18.6 million, up 32.06% from a year prior.
  • Common Equity was $18.4 million for Q3 2025 at Marker Therapeutics, up from $10.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $72.5 million in Q1 2021 to a low of $7.4 million in Q3 2024.
  • A 5-year average of $26.0 million and a median of $18.6 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 56.77% in 2022, then soared 146.84% in 2025.
  • Marker Therapeutics' Common Equity stood at $44.0 million in 2021, then crashed by 55.44% to $19.6 million in 2022, then dropped by 28.31% to $14.1 million in 2023, then soared by 32.06% to $18.6 million in 2024, then fell by 0.91% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Common Equity are $18.4 million (Q3 2025), $10.5 million (Q2 2025), and $14.5 million (Q1 2025).